Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate, or FABAC, called aramchol. Its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH), which constitutes an unmet medical need. The Company has completed three clinical trials of aramchol. The Company focuses on providing a multi-center, double-blind, randomized Phase IIb placebo-controlled clinical trial of aramchol in NASH patients who also suffer from obesity and insulin resistance. The Company is engaged in developing aramchol for the treatment of NASH in patients who also suffer from obesity and insulin resistance.
